PainReform (PRFX) Competitors $1.49 +0.02 (+1.36%) Closing price 04:00 PM EasternExtended Trading$1.49 +0.00 (+0.07%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. AIMD, BTAI, CYCN, ATNF, LIXT, NKGN, PHXM, KZIA, SNSE, and IMNNShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Ainos (AIMD), BioXcel Therapeutics (BTAI), Cyclerion Therapeutics (CYCN), 180 Life Sciences (ATNF), Lixte Biotechnology (LIXT), NKGen Biotech (NKGN), PHAXIAM Therapeutics (PHXM), Novogen (KZIA), Sensei Biotherapeutics (SNSE), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors Ainos BioXcel Therapeutics Cyclerion Therapeutics 180 Life Sciences Lixte Biotechnology NKGen Biotech PHAXIAM Therapeutics Novogen Sensei Biotherapeutics Imunon PainReform (NASDAQ:PRFX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends. Does the media refer more to PRFX or AIMD? In the previous week, PainReform and PainReform both had 1 articles in the media. PainReform's average media sentiment score of 1.87 beat Ainos' score of 0.63 indicating that PainReform is being referred to more favorably in the media. Company Overall Sentiment PainReform Very Positive Ainos Positive Which has higher valuation & earnings, PRFX or AIMD? PainReform has higher earnings, but lower revenue than Ainos. Ainos is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$14.59M-$147.33-0.01Ainos$20K540.51-$14.86M-$6.45-0.40 Do analysts recommend PRFX or AIMD? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of PRFX or AIMD? 37.3% of PainReform shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 10.4% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, PRFX or AIMD? PainReform has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Is PRFX or AIMD more profitable? PainReform's return on equity of 0.00% beat Ainos' return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A N/A N/A Ainos N/A -88.07%-48.60% SummaryPainReform beats Ainos on 8 of the 11 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.96M$2.50B$5.70B$9.51BDividend YieldN/A1.75%4.69%4.01%P/E Ratio-0.019.0528.0720.05Price / SalesN/A757.64448.5799.42Price / CashN/A165.2136.2258.56Price / Book0.725.168.665.87Net Income-$14.59M$30.99M$3.25B$258.55M7 Day Performance2.76%7.74%4.20%2.23%1 Month Performance15.50%16.18%10.82%12.76%1 Year Performance-2.49%-1.03%34.70%19.36% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform0.7939 of 5 stars$1.49+1.4%N/A-8.1%$2.96MN/A-0.014AIMDAinos1.5558 of 5 stars$2.64-4.7%N/A-24.0%$11.61M$20K-0.4140High Trading VolumeBTAIBioXcel Therapeutics3.964 of 5 stars$1.89-1.0%$42.60+2,154.0%-90.8%$11.57M$2.27M-0.1490Gap UpCYCNCyclerion Therapeutics2.5328 of 5 stars$3.37-4.8%N/A-8.5%$11.36M$2M-2.9130Positive NewsATNF180 Life Sciences1.0568 of 5 stars$2.81+49.5%N/A-5.3%$11.35MN/A-0.197Positive NewsEarnings ReportGap UpHigh Trading VolumeLIXTLixte BiotechnologyN/A$3.92-3.4%N/A+79.7%$10.90MN/A-2.704Gap DownNKGNNKGen Biotech0.5901 of 5 stars$0.24flatN/A-83.8%$10.79MN/A-0.05N/AGap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049KZIANovogen4.0194 of 5 stars$8.97-11.6%$14.00+56.1%-44.7%$10.22M$1.51M0.0012Positive NewsSNSESensei Biotherapeutics4.6537 of 5 stars$7.71-1.7%$90.00+1,067.3%-47.8%$9.89MN/A-0.3440IMNNImunon1.9458 of 5 stars$0.56+1.4%$15.50+2,667.9%-58.4%$9.68M$500K-0.4130Stock Split Related Companies and Tools Related Companies AIMD Competitors BTAI Competitors CYCN Competitors ATNF Competitors LIXT Competitors NKGN Competitors PHXM Competitors KZIA Competitors SNSE Competitors IMNN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRFX Stock Alerts